<DOC>
	<DOCNO>NCT01081808</DOCNO>
	<brief_summary>RATIONALE : Giving autologous lymphocyte treat laboratory antibody may stimulate immune system kill tumor cell . Aldesleukin may stimulate lymphocyte kill tumor cell . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving laboratory-treated autologous lymphocytes together aldesleukin GM-CSF may kill tumor cell . PURPOSE : This phase I trial study side effect best dose laboratory-treated autologous lymphocyte give together aldesleukin GM-CSF treating patient recurrent , refractory , metastatic advance solid tumor .</brief_summary>
	<brief_title>Laboratory-Treated Autologous Lymphocytes , Aldesleukin , Sargramostim ( GM-CSF ) Treating Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary Determine safety maximum tolerate dose EGFRBi-armed autologous activate T-cells ( ATC ) administer combination low-dose aldesleukin sargramostim ( GM-CSF ) patient recurrent , refractory , extensive ( metastatic ) advance solid tumor . Secondary Assess clinical outcome base tumor response , overall survival , progression-free survival . Monitor change sera concentration tumor-associated biomarkers respective primary neoplasm ( i.e . carcinoembryonic antigen ( CEA ) ; prostate specific antigen ( PSA ) ; Her2/neu ( HER2 ) ; etc . ) association EGFRBi-armed ATC administration throughout study time point thereafter . Monitor patient serum human anti-mouse antibody ( HAMA ) . Evaluate immune response , may reflect immune augmentation response EGFRBi-armed ATC infusion , peripheral blood mononuclear cell ( PBMC ) sample well purify immune cell population . Investigate proliferation response ex vivo stimulation tumor-specific antigen , serum cytokine profile ( Th1 v Th2 ) , cytotoxicity patient PBMC , interferon gamma ELISPOTS surrogate marker assess generation EGFR-specific cytotoxic T-lymphocytes ( CTL ) . OUTLINE : Peripheral blood mononuclear cell ( PBMCs ) collect 1 2 leukaphereses generation activate T cell ( ATCs ) . The PBMCs activate OKT3 ( anti-CD3 ) expand aldesleukin 14 day . The ATCs arm EGFRBi . Patients receive EGFRBi-armed autologous ATCs IV 30-60 minute twice weekly 4 week ( total 8 infusion ) absence disease progression unacceptable toxicity . Patients also receive low-dose aldesleukin subcutaneously ( SC ) daily sargramostim ( GM-CSF ) SC twice weekly begin 3 day first ATC infusion continue 1 week last ATC infusion . After completion study therapy , patient follow periodically . NOTE : For purpose determine safety maximum tolerate dose EGFRBi-armed ATC , patient enrol dose level study combine patient enrol dose level RWH 349-32 ( NCT00569296 ) : A phase I study Anti-CD3 x Cetuximab-Armed Activated T Cells , Low Dose IL-2 , GM-CSF EGFR-Positive , Advanced Non-Small Cell Lung Cancer ( NSCLC ) count toward dose level cohort . A total three patient enrol form either two trial treat dose level , least one NSCLC patient representative protocol 349-32 enrol evaluate dose level .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria Histologically cytologically confirm solid tumor type ( ex . Head Neck Squamous Cell Carcinoma , Colorectal , Pancreatic , Gastric , Esophageal , Renal , Prostate , Breast Ovarian cancer , etc . ) ; high risk , recurrent , refractory , metastatic disease ≥ 1 prior firstline regimen ( chemotherapy radiotherapy ) Documented EGFRpositive disease ( expression level ) immunohistochemistry ( IHC ) No clinical evidence active brain metastasis ; patient brain metastasis eligible provide received definitive radiotherapy chemotherapy and/or undergone surgical resection brain metastases No prior hematological malignancy Karnofsky performance status ( PS ) 60100 % OR RCOG PS 02 Life expectancy ≥ 3 month Not pregnant nursing Fertile patient must use contraception Granulocytes ≥ 1,000/mm3 Platelet count ≥ 50,000/mm3 Hemoglobin ≥ 8g/dL BUN ≤ 2.0 time normal Serum creatinine ≤ 2.0mg/dL Bilirubin ≤ 1.5 time normal ( without liver metastasis ) Hepatitis B surface antigen HIV negative LVEF ≥ 45 % rest MUGA No evidence depress left ventricular function No malignancy , except follow : History curatively treat situ squamous cell carcinoma basal cell carinoma skin History curatively treat malignancy ( except hematologic origin ) patient remain complete remission &gt; 5 year complete therapy ( documented history , physical exam , tumor marker , radiology scan ) Exclusion Criteria Serious medical psychiatric illness would preclude give informed consent receive intensive treatment Recent myocardial infarction ( within past year ) Current angina/coronary symptom require medication Clinical evidence congestive heart failure require medical management ( irrespective MUGA result ) Systolic blood pressure ( BP ) ≥ 140 mm Hg diastolic BP ≥ 90 Hg ; patient elevate BP must control antihypertensive medication least 7 day prior infusion Clinical evidence active brain metastasis Prior/Concurrent Therapy More 4 week since prior chemotherapy radiotherapy At least 4 week since prior cetuximab small molecule EGFRinhibitors include , limited , gefitinib erlotinib hydrochloride No concurrent radiotherapy No concurrent steroid except treatment adrenal failure , septic shock , pulmonary toxicity hormone nondiseaserelated condition ( e.g. , insulin diabetes )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>PhaseI</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>biomarkers</keyword>
	<keyword>T cell</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Epidermal Growth Factor Receptor</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>Lymphocytes</keyword>
	<keyword>Autologous</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Refractory</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Anti-Retroviral Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Neoplasms</keyword>
</DOC>